The agglutination test 
Introduction
Since the first description of a serological test 27 patients whose pretreatment sera (group 2) had shown low titres and who were tested again after two months' of chemotherapy (group 5). Sera from group 1 had already been sent to Midhurst for routine testing by Dr Nicholls as an aid to diagnosis. The 98 family contacts who provided group 3 sera all had chest radiographs taken within seven days of blood collection and 97 also underwent a Mantoux test with 1 TU purified protein derivative RT23 at the same time. A repeat radiograph was obtained in 76 of these people four to 12 months later. All radiographs were normal.
Sera from Singapore were flown frozen to Hammersmith. All sera at Hammersmith were stored at -20°C. The agglutination tests were carried out as described by Nicholls,10 who provided the antigen suspensions used. All of the tests were read by observer 1, whose results are presented throughout, and most by observer 2 also. The origin of the sera was not disclosed to the observer until after the tests had been read.
Results
The results in group 1 sera, tested in several batches at Midhurst and Hammersmith (table I), agreed fairly well (correlation coefficient, r = 0 64). As might have been expected, observer 1 and observer 2 agreed more closely in their readings (not tabulated here) of the same test on 190 sera at Hammersmith (r = 0 85). In view of the claim that occasional patients with culture-positive tuberculosis might have an initial low titre in the test followed a few weeks later by a diagnostic rising titre,'1 tests were carried out on group 5 sera, which were samples obtained two months after the start of chemotherapy from 27 patients whose pretreatment sera had low titres (group 2) (table III). There was no evidence of any change during the period: a titre of 50 or more was obtained in 14 pretreatment sera and in 15 taken at two months.
Comment
The similarity of the results of the agglutination test in patients with active pulmonary tuberculosis; in healthy contacts, whether or not they were positive on the Mantoux test; and in patients with non-tuberculous conditions indicates that the test has no value in diagnosing active tuberculosis and should not be requested for this purpose. This failure to confirm the claims from the Midhurst Medical Research Institute does not seem to be due to differences in the method used in the two laboratories since the results obtained at Midhurst and Hammersmith agreed reasonably well. In particular, the Midhurst laboratory found a similar number of negative results among the sera from patients with active tuberculosis and positive results among sera from the non-tuberculous controls.
Summary
The plasma half lives of antipyrine, paracetamol, and lignocaine given by mouth were measured in 23 patients with stable chronic liver diseases of varying severity. Fifteen patients received all three drugs and 19 at least Prolongation of the half lives of all three drugs was significantly correlated with an increase of the vitamin-K1-corrected prothrombin time ratio and a reduction in serum albumin concentration. There was no correlation with serum bilirubin concentration or serum alanine aminotransferase activity. This suggests that impaired drug elimination was related to depressed hepatic protein synthesis. Considerable prolongation of the half life of one drug was invariably associated with delayed elimination of the others. The half life of lignocaine, however, was always the most prolonged and was a highly sensitive indicator of hepatic dysfunction. The pharmacokinetic characteristics of a drug as well as the severity of liver disease should be taken into account when considering drug dosage in patients with chronic liver disease.
